Telix Pharmaceuticals announces first patient dosed in Phase II CA-NINE trial

Telix Pharmaceuticals announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix’s first-in-class investigational PET1 agent, TLX250-CDx in recurrent clear cell renal cell carcinoma after surgery. ‘CA-NINE’2 – led by Professor Brian Shuch at University of California, Los Angeles – is a Phase II prospective, single-centre trial comparing the diagnostic performance of TLX250-CDx PET/CT3 to conventional imaging in 91 patients with intermediate-to-high risk ccRCC post-surgery. The investigator-initiated trial is designed to identify ccRCC where it has recurred, including metastatic disease, and is one of multiple trials either underway or planned, which may inform future label expansion for TLX250-CDx.